abbvie

abbvie

NYSE:ABBV
AbbVie

Chart

Detailed Quote

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Featured Articles and Interviews
Dried mushrooms in the center are surrounded by translucent capsules on a white background.

Executive Order Sparks New Phase for Psychedelic Biotech, Risks Remain

A glass flask on a reflective table with overlaid stock market charts and numerical data, including text reading: 0.00%.

Anthropic Inks US$400 Million Deal for AI Biotech Startup Coefficient Bio

Dollar bills, pink and white pills in blister packs, and a nasal spray on a blue background.

Blackstone Raises Record US$6.3 Billion for Largest Life Sciences Fund

Press Releases

AbbVie Announces TEPKINLY® in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The Conversation (0)